Genesystem Co., Ltd. (KOSDAQ:363250)
South Korea · Delayed Price · Currency is KRW 4,250.00
+190.00 (4.68%)
At close: Sep 11, 2026
Genesystem Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Operating Revenue | 1,010 | 381.36 | 1,208 | 897.03 | 3,653 |
Other Revenue | 0 | - | 0 | 0 | - |
| 1,010 | 381.36 | 1,208 | 897.03 | 3,653 | |
Revenue Growth | -4.59% | -68.42% | 34.64% | -75.44% | - |
Cost of Revenue | 3,018 | 2,846 | 3,028 | 2,483 | 2,486 |
Gross Profit | -2,008 | -2,465 | -1,820 | -1,586 | 1,167 |
Selling, General & Admin | 3,154 | 3,658 | 3,885 | 4,119 | 3,855 |
Research & Development | 2,138 | 2,689 | 3,344 | 3,425 | 3,354 |
Amortization of Goodwill & Intangibles | 240.98 | 598.69 | 776.44 | 196.51 | 73.49 |
Other Operating Expenses | 88.15 | 97.64 | 85.56 | 76.6 | 72.81 |
Operating Expenses | 5,844 | 7,225 | 8,296 | 7,898 | 7,772 |
Operating Income | -7,852 | -9,690 | -10,116 | -9,484 | -6,605 |
Interest Expense | -121.14 | -124.58 | -136.25 | -133.61 | -95.47 |
Interest & Investment Income | 55.98 | 76.06 | 300.54 | 363.75 | 205.31 |
Earnings From Equity Investments | - | - | - | 882.76 | - |
Currency Exchange Gain (Loss) | 51.58 | -5.75 | 70.28 | 76.04 | 234.36 |
Other Non Operating Income (Expenses) | 18.32 | 8.48 | 7.12 | 124.59 | 29.27 |
EBT Excluding Unusual Items | -7,847 | -9,736 | -9,874 | -8,171 | -6,231 |
Gain (Loss) on Sale of Investments | 98.04 | 94.84 | 194.97 | 258.36 | -825.27 |
Gain (Loss) on Sale of Assets | 133.55 | 5 | -0.18 | - | -3.14 |
Asset Writedown | -6,275 | -6,275 | - | - | - |
Pretax Income | -13,890 | -15,911 | -9,679 | -7,913 | -7,060 |
Income Tax Expense | -1,167 | -1,242 | -150.73 | 146.41 | 1,936 |
Earnings From Continuing Operations | -12,723 | -14,669 | -9,529 | -8,059 | -8,996 |
Minority Interest in Earnings | 2,441 | 2,714 | 613.41 | 143.55 | - |
Net Income | -10,282 | -11,955 | -8,915 | -7,915 | -8,996 |
Net Income to Common | -10,282 | -11,955 | -8,915 | -7,915 | -8,996 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 7 |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 7 |
Shares Change | 6.41% | -0.46% | -1.47% | 0.69% | - |
EPS (Basic) | -1418.71 | -1754.01 | -1302.00 | -1139.05 | -1303.50 |
EPS (Diluted) | -1418.71 | -1754.01 | -1302.00 | -1139.05 | -1303.50 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -8,806 | -7,103 | -7,595 | -8,174 | -6,655 |
Free Cash Flow Per Share | -1215.08 | -1042.12 | -1109.26 | -1176.31 | -964.32 |
Gross Margin | -198.81% | - | -150.69% | -176.81% | 31.96% |
Operating Margin | -777.39% | -2541.03% | -837.58% | -1057.33% | -180.80% |
Profit Margin | -1017.98% | -3134.97% | -738.17% | -882.41% | -246.26% |
Free Cash Flow Margin | -871.87% | -1862.60% | -628.89% | -911.27% | -182.18% |
EBITDA | -7,284 | -8,672 | -8,873 | -8,939 | -6,219 |
EBITDA Margin | - | - | - | - | -170.23% |
D&A For EBITDA | 567.86 | 1,018 | 1,242 | 545.39 | 386.3 |
EBIT | -7,852 | -9,690 | -10,116 | -9,484 | -6,605 |
EBIT Margin | - | - | - | - | -180.80% |
Advertising Expenses | - | 248.48 | 182.95 | 281.68 | 239.36 |